Jhanelle E. Gray

Jhanelle Gray is an expert thoracic oncologist and clinical investigator focusing on mechanisms of resistance to ALK inhibitors and strategies to overcome compound ALK mutations that arise through sequential therapy. She has contributed to landmark studies of lorlatinib demonstrating activity against G1202R and other compound resistance mutations. Her research program characterizes the evolutionary landscape of ALK-positive NSCLC under therapeutic pressure. She leads phase I/II trials of next-generation therapies for patients with compound ALK mutations.